Clinical Trials
25 trialsNCT06532279 2026-05-04
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NRG Oncology
Phase 2 Recruiting
NCT06706401 2026-04-24
LYSARI
Centre Leon Berard
Phase 3 Recruiting
NCT07209189 2026-04-23
(NeoScorch HN)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT05075980 2026-04-13
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Mayo Clinic
Phase 2 Active not recruiting
NCT04030455 2026-03-09
Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03174275 2026-02-23
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT02918955 2025-11-20
UPFRONT-NECK
Insel Gruppe AG, University Hospital Bern
Phase 3 Completed
NCT02586207 2025-10-07
Pembrolizumab in Combination With CRT for LA-SCCHN
Sanford Health
Phase 1 Completed
NCT02113878 2024-11-05
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
Dana-Farber Cancer Institute
Phase 1 Completed
NCT06611137 2024-09-26
SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx
Sun Yat-sen University
Phase 2 Recruiting
NCT03028766 2024-09-19
WISTERIA
University of Birmingham
Phase 1 Completed
NCT04541355 2024-06-28
Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin
University of California, San Francisco
Phase 2 Completed
NCT04892875 2023-11-30
PANTHEoN
Vanderbilt-Ingram Cancer Center
Phase 1 Withdrawn
NCT01633541 2023-07-20
Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT02760667 2023-06-27
Induction Chemotherapy Followed by Surgery for Locally Advanced Head and Neck Cancer
George Washington University
Phase 2 Unknown
NCT00003777 2022-01-26
Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer
Abramson Cancer Center at Penn Medicine
Phase 2 Terminated
NCT04995120 2022-01-18
INSIGHT
Fudan University
Phase 2 Unknown
NCT00833261 2020-08-21
Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT00169182 2019-02-15
Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma
Groupe Oncologie Radiotherapie Tete et Cou
Phase 3 Completed
NCT00117572 2018-04-09
DeCIDE
University of Chicago
Phase 3 Completed
NCT01216020 2018-01-17
CTXMAB+RT
Azienda USL 4 Prato
Phase 2 Terminated
NCT00599131 2015-12-03
Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT00508664 2015-06-02
DeLOS II
University of Leipzig
Phase 2 Completed
NCT00169247 2011-06-27
Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation
Groupe Oncologie Radiotherapie Tete et Cou
Phase 2 Completed
NCT01073683 2010-03-05
Induction Docetaxel/Cisplatin/5-fluorouracil (TPF) as Selector for Chemo Radiation Therapy (RT) Versus Partial Laryngectomy in Advanced Laryngeal Cancer
Rabin Medical Center
Phase 2 Unknown